• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Rheumatoid Arthritis - Pipeline Review, H1 2012 Product Image

Rheumatoid Arthritis - Pipeline Review, H1 2012

  • ID: 2075475
  • February 2012
  • 348 pages
  • Global Markets Direct

Rheumatoid Arthritis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H1 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rheumatoid Arthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Rheumatoid Arthritis
Rheumatoid Arthritis Therapeutics under Development by Companies
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Rheumatoid Arthritis Therapeutics – Products under Development by Companies
Rheumatoid Arthritis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Rheumatoid Arthritis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
Inovio Biomedical Corporation
MedImmune LLC
Isis Pharmaceuticals, Inc.
Biotest AG
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Ablynx
Micromet, Inc.
Novo Nordisk A/S
Plexxikon Inc.
BioLineRx, Ltd.
arGentis Pharmaceuticals, LLC
MediGene AG
Celltrion, Inc.
TiGenix NV
Pacira Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Biocon Limited
Daewoong Pharmaceutical Co., Ltd.
Dong-A Pharmaceutical Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Maxygen, Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Santarus, Inc.
Teva Pharmaceutical Industries Limited
Toyama Chemical Co. Ltd
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Genmab A/S
novosom AG
CEL-SCI Corporation
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Incyte Corporation
Vernalis plc
Merck KGaA
Bone Medical Limited
4SC AG
3SBio Inc.
Addex Pharmaceuticals
EntreMed, Inc.
Evotec Aktiengesellschaft
Genesis Research and Development Corporation Ltd.
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
IMMUNOMEDICS, INC
Can-Fite BioPharma Ltd.
Idera Pharmaceuticals, Inc.
Karo Bio
Almirall, S.A.
Lupin Limited
Medivir AB
PROLOR Biotech, Inc.
Novogen Limited
Nutra Pharma Corporation
Compugen Ltd.
Lexicon Pharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Chelsea Therapeutics, Inc.
CombinatoRx, Incorporated
Yuhan Corporation
Zenotech Laboratories Limited
Regeneron Pharmaceuticals, Inc.
Unigene Laboratories, Inc.
Pharmacyclics, Inc.
Protalix BioTherapeutics, Inc.
Tolerx, Inc.
Antisoma plc
MorphoSys AG
Boryung Pharmaceutical Co., Ltd.
Hanall Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
AnGes MG, Inc.
Biotie Therapies Corp.
Transition Therapeutics Inc.
LTT Bio-Pharma Co., Ltd.
Galapagos NV
Synta Pharmaceuticals Corp.
CrystalGenomics, Inc.
Sareum Holdings plc
Protalex, Inc.
Proximagen Neuroscience plc.
Newron Pharmaceuticals S.p.A.
Simcere Pharmaceutical Group
Piramal Life Sciences Limited
Morphotek, Inc.
Chroma Therapeutics Ltd.
Advinus Therapeutics Pvt. Ltd.
Affimed Therapeutics AG
Ambit Biosciences Corporation
AnaMar Medical AB
Viron Therapeutics, Inc.
Immupharma Plc
Palau Pharma S.A
Philogen S.p.A.
Probiodrug AG
Acceleron Pharma, Inc.
Phenex Pharmaceuticals AG
Neovacs SA
MIKA Pharma GmbH
CREABILIS Therapeutics S.r.l.
Artielle ImmunoTherapeutics, Inc.
Aquinox Pharmaceuticals Inc.
Amura Holdings Ltd.
JADO Technologies GmbH.
AnaptysBio, Inc.
IMMD Inc.
Circassia Holdings Ltd.
Funxional Therapeutics Ltd
Oxagen Limited
Catabasis Pharmaceuticals, Inc.
Recoly N.V.
Opsona Therapeutics Ltd.
Asahi Kasei Pharma
Vaccinex, Inc.
Syntrix Biosystems, Inc.
Peptimmune, Inc.
S-BIO Pte Ltd
Deciphera Pharmaceuticals, LLC
Indus Biotech Private Limited
NovImmune SA
Txcell SA
Theraclone Sciences, Inc.
Theracos, Inc.
TcL Pharma SAS
Versartis, Inc.
Cardax Pharmaceuticals, Inc.
Virobay Inc.
Myriad Pharmaceuticals, Inc.
Inimex Pharmaceuticals, Inc.
Karus Therapeutics Ltd
Logical Therapeutics, Inc.
Omeros Corporation
Xencor, Inc.
BioStar Pharmaceuticals, Inc.
Cornerstone Therapeutics Inc.
Acetylon Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
SBI Biotech Co., Ltd.
CBio Limited
VentiRx Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc.
AB Science
Resolvyx Pharmaceuticals, Inc
OncoImmune, Inc.
Avesthagen Limited
Nuon Therapeutics, Inc.
KAHR medical Ltd.
SuppreMol GmbH
Viromed Co., Ltd.
Ferring Pharmaceuticals, Inc.
Aphoenix, Inc.
Advanced Cancer Therapeutics
Domainex Ltd.
Cellceutix Pharmaceuticals, Inc.
Dynamix Pharmaceuticals Ltd.
Amplimmune, Inc.
Lycera Corp.
OHR Pharmaceutical Inc.
ImmunoFrontier, Inc.
Femta Pharmaceuticals, Inc.
UCB S.A.
Cellmid Ltd
Mebiopharm Co., Ltd.
ToleroTech Inc.
Rheumatoid Arthritis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
REGN88 - Drug Profile
LY2127399 - Drug Profile
Tofacitinib - Drug Profile
Arzerra - Drug Profile
AIN457 - Drug Profile
Actemra - Drug Profile
Cimzia - Drug Profile
Arcoxia - Drug Profile
T-614 - Drug Profile
Orencia - Drug Profile
Iguratimod - Drug Profile
Lodotra - Drug Profile
LT-NS001 - Drug Profile
AB1010 - Drug Profile
Leflunomide - Drug Profile
Leflunomide + Sulfasalazine + Hydroxychloroquine - Drug Profile
Methotrexate + Sulfasalazine + Hydroxychloroquine - Drug Profile
Zushima - Drug Profile
R788 - Drug Profile
Hydroxychloroquine - Drug Profile
CDP870 + Methotrexate - Drug Profile
Methotrexate + Triamcinolone Hexacetonide + Adalimumab - Drug Profile
Tocilizumab + Chloroquine + Hydroxychloroquine + Parenteral Gold + Sulfasalazine + Azathioprine + Leflunomide - Drug Profile
Simponi - Drug Profile
CT-P13 - Drug Profile
PG 201 - Drug Profile
T-614 + Methotrexate - Drug Profile
HD203 - Drug Profile
Biosimilar Etanercept - Drug Profile
RoACTEMRA + Methotrexate - Drug Profile
Rheumatoid Arthritis Therapeutics – Drug Profile Updates
Rheumatoid Arthritis Therapeutics – Discontinued Products
Rheumatoid Arthritis Therapeutics - Dormant Products
Rheumatoid Arthritis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Rheumatoid Arthritis, H1 2012
Products under Development for Rheumatoid Arthritis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Development by Companies, H1 2012 (Contd..8)
Number of Products under Development by Companies, H1 2012 (Contd..9)
Number of Products under Development by Companies, H1 2012 (Contd..10)
Number of Products under Development by Companies, H1 2012 (Contd..11)
Number of Products under Development by Companies, H1 2012 (Contd..12)
Number of Products under Development by Companies, H1 2012 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Development by Companies, H1 2012 (Contd..10)
Products under Development by Companies, H1 2012 (Contd..11)
Products under Development by Companies, H1 2012 (Contd..12)
Products under Development by Companies, H1 2012 (Contd..13)
Products under Development by Companies, H1 2012 (Contd..14)
Products under Development by Companies, H1 2012 (Contd..15)
Products under Development by Companies, H1 2012 (Contd..16)
Products under Development by Companies, H1 2012 (Contd..17)
Products under Development by Companies, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Biogen Idec Inc., H1 2012
Amgen Inc., H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Genentech, Inc., H1 2012
Inovio Biomedical Corporation, H1 2012
MedImmune LLC, H1 2012
Isis Pharmaceuticals, Inc., H1 2012
Biotest AG, H1 2012
Merck & Co., Inc., H1 2012
Santen Pharmaceutical Co., Ltd., H1 2012
Ablynx, H1 2012
Micromet, Inc., H1 2012
Novo Nordisk A/S, H1 2012
Plexxikon Inc., H1 2012
BioLineRx, Ltd., H1 2012
arGentis Pharmaceuticals, LLC, H1 2012
MediGene AG, H1 2012
Celltrion, Inc., H1 2012
TiGenix NV, H1 2012
Pacira Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
Astellas Pharma Inc., H1 2012
Biocon Limited, H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Maxygen, Inc., H1 2012
Mitsubishi Tanabe Pharma Corporation, H1 2012
Pfizer Inc., H1 2012
Rigel Pharmaceuticals, Inc., H1 2012
Santarus, Inc., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Toyama Chemical Co. Ltd, H1 2012
Vertex Pharmaceuticals Incorporated, H1 2012
Zydus Cadila Healthcare Limited, H1 2012
Genmab A/S, H1 2012
novosom AG, H1 2012
CEL-SCI Corporation, H1 2012
Celgene Corporation, H1 2012
Onyx Pharmaceuticals, Inc., H1 2012
Incyte Corporation, H1 2012
Vernalis plc, H1 2012
Merck KGaA, H1 2012
Bone Medical Limited, H1 2012
4SC AG, H1 2012
3SBio Inc., H1 2012
Addex Pharmaceuticals, H1 2012
EntreMed, Inc., H1 2012
Evotec Aktiengesellschaft, H1 2012
Genesis Research and Development Corporation Ltd., H1 2012
GW Pharmaceuticals plc, H1 2012
Hollis-Eden Pharmaceuticals, Inc., H1 2012
IMMUNOMEDICS, INC, H1 2012
Can-Fite BioPharma Ltd., H1 2012
Idera Pharmaceuticals, Inc., H1 2012
Karo Bio, H1 2012
Almirall, S.A., H1 2012
Lupin Limited, H1 2012
Medivir AB, H1 2012
PROLOR Biotech, Inc., H1 2012
Novogen Limited, H1 2012
Nutra Pharma Corporation, H1 2012
Compugen Ltd., H1 2012
Lexicon Pharmaceuticals, Inc., H1 2012
Accentia Biopharmaceuticals, Inc., H1 2012
Portola Pharmaceuticals, Inc., H1 2012
Chelsea Therapeutics, Inc., H1 2012
CombinatoRx, Incorporated, H1 2012
Yuhan Corporation, H1 2012
Zenotech Laboratories Limited, H1 2012
Regeneron Pharmaceuticals, Inc., H1 2012
Unigene Laboratories, Inc., H1 2012
Pharmacyclics, Inc., H1 2012
Protalix BioTherapeutics, Inc., H1 2012
Tolerx, Inc., H1 2012
Antisoma plc, H1 2012
MorphoSys AG, H1 2012
Boryung Pharmaceutical Co., Ltd., H1 2012
Hanall Pharmaceutical Co., Ltd., H1 2012
LG Life Sciences, Ltd, H1 2012
AnGes MG, Inc., H1 2012
Biotie Therapies Corp., H1 2012
Transition Therapeutics Inc., H1 2012
LTT Bio-Pharma Co., Ltd., H1 2012
Galapagos NV, H1 2012
Synta Pharmaceuticals Corp., H1 2012
CrystalGenomics, Inc., H1 2012
Sareum Holdings plc, H1 2012
Protalex, Inc., H1 2012
Proximagen Neuroscience plc., H1 2012
Newron Pharmaceuticals S.p.A., H1 2012
Simcere Pharmaceutical Group, H1 2012
Piramal Life Sciences Limited, H1 2012
Morphotek, Inc., H1 2012
Chroma Therapeutics Ltd., H1 2012
Advinus Therapeutics Pvt. Ltd., H1 2012
Affimed Therapeutics AG, H1 2012
Ambit Biosciences Corporation, H1 2012
AnaMar Medical AB, H1 2012
Viron Therapeutics, Inc., H1 2012
Immupharma Plc, H1 2012
Palau Pharma S.A, H1 2012
Philogen S.p.A., H1 2012
Probiodrug AG, H1 2012
Acceleron Pharma, Inc., H1 2012
Phenex Pharmaceuticals AG, H1 2012
Neovacs SA, H1 2012
MIKA Pharma GmbH, H1 2012
CREABILIS Therapeutics S.r.l., H1 2012
Artielle ImmunoTherapeutics, Inc., H1 2012
Aquinox Pharmaceuticals Inc., H1 2012
Amura Holdings Ltd., H1 2012
JADO Technologies GmbH., H1 2012
AnaptysBio, Inc., H1 2012
IMMD Inc., H1 2012
Circassia Holdings Ltd., H1 2012
Funxional Therapeutics Ltd, H1 2012
Oxagen Limited, H1 2012
Catabasis Pharmaceuticals, Inc., H1 2012
Recoly N.V., H1 2012
Opsona Therapeutics Ltd., H1 2012
Asahi Kasei Pharma, H1 2012
Vaccinex, Inc., H1 2012
Syntrix Biosystems, Inc., H1 2012
Peptimmune, Inc., H1 2012
S-BIO Pte Ltd, H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
Indus Biotech Private Limited, H1 2012
NovImmune SA, H1 2012
Txcell SA, H1 2012
Theraclone Sciences, Inc., H1 2012
Theracos, Inc., H1 2012
TcL Pharma SAS, H1 2012
Versartis, Inc., H1 2012
Cardax Pharmaceuticals, Inc., H1 2012
Virobay Inc., H1 2012
Myriad Pharmaceuticals, Inc., H1 2012
Inimex Pharmaceuticals, Inc., H1 2012
Karus Therapeutics Ltd, H1 2012
Logical Therapeutics, Inc., H1 2012
Omeros Corporation, H1 2012
Xencor, Inc., H1 2012
BioStar Pharmaceuticals, Inc., H1 2012
Cornerstone Therapeutics Inc., H1 2012
Acetylon Pharmaceuticals, Inc., H1 2012
Trillium Therapeutics Inc., H1 2012
SBI Biotech Co., Ltd., H1 2012
CBio Limited, H1 2012
VentiRx Pharmaceuticals, Inc., H1 2012
KaloBios Pharmaceuticals, Inc., H1 2012
AB Science, H1 2012
Resolvyx Pharmaceuticals, Inc, H1 2012
OncoImmune, Inc., H1 2012
Avesthagen Limited, H1 2012
Nuon Therapeutics, Inc., H1 2012
KAHR medical Ltd., H1 2012
SuppreMol GmbH, H1 2012
Viromed Co., Ltd., H1 2012
Ferring Pharmaceuticals, Inc., H1 2012
Aphoenix, Inc., H1 2012
Advanced Cancer Therapeutics, H1 2012
Domainex Ltd., H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Dynamix Pharmaceuticals Ltd., H1 2012
Amplimmune, Inc., H1 2012
Lycera Corp., H1 2012
OHR Pharmaceutical Inc., H1 2012
ImmunoFrontier, Inc., H1 2012
Femta Pharmaceuticals, Inc., H1 2012
UCB S.A., H1 2012
Cellmid Ltd, H1 2012
Mebiopharm Co., Ltd., H1 2012
ToleroTech Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Rheumatoid Arthritis Therapeutics – Drug Profile Updates
Rheumatoid Arthritis Therapeutics – Discontinued Products
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..1)
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..2)
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..3)
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..4)
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..5)
Rheumatoid Arthritis Therapeutics – Discontinued Products (Contd..6)
Rheumatoid Arthritis Therapeutics – Dormant Products
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..1)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..2)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..3)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..4)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..5)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..6)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..7)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..8)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..9)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..10)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..11)
Rheumatoid Arthritis Therapeutics – Dormant Products (Contd..12)

List of Figures
Number of Products under Development for Rheumatoid Arthritis, H1 2012
Products under Development for Rheumatoid Arthritis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos